About 2025 Event

Welcome to the 4th In Vivo Cell Engineering & Gene Editing Summit!

Join C-suite Executives, VPs and Directors as they provide exclusive insights into in vivo CAR optimizations, mRNA and gene editing therapies to expand therapeutics options and treatment accessibility.

With an 82% new speaker faculty, this summit offers fresh insights into reducing variability in translational outcomes while exploring strategies to de-target the liver and expand treatment possibilities. You’ll also discover breakthrough innovations from 12 new companies showcasing the latest technologies driving progress in the in vivo cell and gene field.

If you want a sneak peak of the insights shared on advancing safe and targeted in vivo delivery of therapeutic modalities, view the agenda!

Explore What this Year Has to Offer

Join Pioneers in In Vivo Cell Engineering & Gene Editing To:

Uncover new research into drug and tissue targeting approaches, delivery vehicle optimization and the latest IND data to enhance treatment specificity and overcome off-target toxicity with NanoCell Therapeutics, Alaya.Bio, Cytodigm, Singular Immune, Ensoma and Capstan Therapeutics
Identify effective preclinical models to ensure effective translatable data and streamline the IND approval process with Carisma Therapeutics and Exuma Biotech
Pinpoint the most effective delivery vehicle for your CAR, mRNA or gene editing treatment to combat off-target and delivery system toxicity with Beam Therapeutics, NanoCell Therapeutics, Singular Immune and AbbVie
Clarify regulatory requirements in this everchanging space to achieve safety and efficacy data for your therapy and navigate the path to the clinic with insights from Umoja Biopharma and CorriXR Therapeutics
Gain insights into an investors mindset to ensure the commercial viability of your treatments and facilitate collaboration and investment opportunities with Qiming Venture Partners
Find Out More!

Who Can You Meet?

2025 Companies (March)
Join the Line-up, Register Now

Hear from the 2024 Attendees

‘There was a good variety of topics and approaches discussed by presenters in relation to the in vivo space. Having experienced and established presenters was helpful to those newer to the space.’

Amanda Toreki, Associate Scientist, Cabaletta Bio

‘Great speakers, relevant companies, with some new smaller companies getting exposure and intimate setting for networking.’

Michael Klichinsky, Co-Founder & Chief Scientific Officer, Carisma Therapeutics

‘The small nature of the conference made for a very nice opportunity to network with others in the field and share our experiences, future expectations, and concerns about the field.’

Matthew Spindler, Vice President, Research, GigaMune

‘The lectures as well as the discussions were very relevant and interesting. The forum in which it was conducted was great, it allowed for questions and discussions.’

Hangmesh Cassim, Associate Scientist, Cabaletta Bio

"The conference was nicely organized, represented by key opinion leaders in the field and small but engaging audience. That made the discussion very fruitful."

Dharini Shah, Senior Director, Research & Immunology, Sanofi

View the Full Agenda for More Information on:

        • 21+ In Vivo C-Suite Executives, VPs and Directors
        • 20+ Exclusive Sessions
        • 2 Interactive Deep-Dive Workshops
        • 8+ Hours of Industry Networking

                  & Much More!

Explore Here
Event-Guide-Cover-10-02-25
2025 Agenda
Register
Become a Partner